A Phase 1 Dose Escalation Trial of ZG006 in Patients With Small Cell Lung Cancer
Phase 1
30
about 2.2 years
18–75
6 sites in CA, FL, KY +2
About this study
This trial is testing a treatment called ZG006 for people with small cell lung cancer who have not responded to or cannot tolerate standard treatments. The goal is to find the best dose of ZG006 that can be safely used in future studies.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take ZG006
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Maximum Tolerated Dose (MTD) of ZG006, Number of participants with adverse events (AEs), Number of participants with serious adverse events (SAEs), The incidence of dose-limiting toxicity (DLT)
Secondary: AUC from time zero to the last quantifiable concentration after dosing (AUC[0-t]) of ZG006, Disease control rate (DCR), Duration of response (DOR), Maximum plasma concentration (Cmax) of ZG006, Objective response rate (ORR), Terminal phase half-life (t1/2) of ZG006, Time to peak concentration (Tmax)
Oncology